Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.76 |
| ▸ | ATM | Q13315 | 3/20 | 0.74 |
| ▸ | USP2 | O75604 | 3/20 | 0.74 |
| ▸ | CFTR | P13569 | 1/20 | 0.74 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.74 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PRKDC | P78527 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | CSF1R | P07333 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | GSK3A | P49840 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15006531 | 0.90 | ABCB1 (0.74) | ABCB1ATMUSP2CFTRPAX8 | |
| SCHEMBL13881098 | 0.90 | ABCB1 (0.74) | ABCB1ATMUSP2CFTRPAX8 | |
| SCHEMBL14350757 | 0.90 | ABCB1 (0.61) | ABCB1ATMUSP2CFTRPAX8 | |
| SCHEMBL12173205 | 0.89 | ABCB1 (0.72) | ABCB1ATMUSP2CFTRPAX8 | |
| SCHEMBL20216438 | 0.88 | ABCB1 (0.71) | ABCB1ATMUSP2CFTRPAX8 | |
| SCHEMBL20041379 | 0.88 | ABCB1 (0.71) | ABCB1ATMUSP2CFTRPAX8 | |
| SCHEMBL10167878 | 0.88 | ABCB1 (0.79) | ABCB1ATMUSP2CFTRPAX8 | |
| SCHEMBL16024743 | 0.88 | ABCB1 (0.79) | ABCB1ATMUSP2CFTRPAX8 | |
| SCHEMBL20216437 | 0.88 | ABCB1 (0.70) | ABCB1ATMUSP2CFTRPAX8 | |
| SCHEMBL268381 | 0.87 | ABCB1 (1.00) | ABCB1ATMUSP2CFTRPAX8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021053205-A1 | CHROMENE-4-ONE DERIVATIVES AS BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) MIMETICS | FLORATEK PHARMA AG (CH) | 2021-03-25 | — | — | WO | disclosed |
| US-10845368-B2 | Nanoparticles for mitochondrial trafficking of agents | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| US-10398663-B2 | Mitochondrial delivery of 3-bromopyruvate | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-10004809-B2 | Precise delivery of therapeutic agents to cell mitochondria for anti-cancer therapy | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION INC. (US) | 2018-06-26 | — | — | US | disclosed |
| EP-2814496-B1 | NANOPARTICLES FOR MITOCHONDRIAL TRAFFICKING OF AGENTS | UNIV GEORGIA (US) | 2018-04-11 | — | — | EP | disclosed |
| US-20180066004-A9 | MITOCHONDRIA-TARGETING PLATINUM(IV) PRODRUG | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2018-03-08 | — | — | US | disclosed |
| US-9901616-B2 | Apoptosis-targeting nanoparticles | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2018-02-27 | — | — | US | disclosed |
| US-20170216219-A1 | THERAPEUTIC NANOPARTICLES FOR ACCUMULATION IN THE BRAIN | NATIONAL INSTITUTES OF HEALTH | 2017-08-03 | — | — | US | disclosed |
| US-20170087167-A1 | MODIFICATION OF DRUGS FOR INCORPORATION INTO NANOPARTICLES | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2017-03-30 | — | — | US | disclosed |
| US-20170037071-A1 | MITOCHONDRIA-TARGETING PLATINUM(IV) PRODRUG | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2017-02-09 | — | — | US | disclosed |
| US-20170014361-A1 | MITOCHONDRIAL DELIVERY OF 3-BROMOPYRUVATE | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2017-01-19 | — | — | US | disclosed |
| US-20160184333-A1 | MITOCHONDRIA-TARGETED ANTI-TUMOR AGENTS | UNIVERSITY OF MASSACHUSETTS | 2016-06-30 | — | — | US | disclosed |
| US-20140142121-A1 | MITOCHONDRIA-TARGETED ANTI-TUMOR AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-05-22 | — | — | US | disclosed |
| WO-2011133879-A2 | COMBINATION THERAPIES WITH MITOCHONDRIAL-TARGETED ANTI-TUMOR AGENTS | UNIVERSITY OF MASSACHUSETTS (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2009036092-A2 | MITOCHONDRIA-TARGETED ANTI-TUMOR AGENTS | UNIVERSITY OF MASSACHUSETTS (US) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10004809-B2 | Precise delivery of therapeutic agents to cell mitochondria for anti-cancer therapy | SLC25A1, HADHA, CS | ABCB1 814/4885ATM 1544/4885USP2 1342/4885 |
| US-20180066004-A9 | MITOCHONDRIA-TARGETING PLATINUM(IV) PRODRUG | MT-ND4, MT-CO3, COX6A1 | ABCB1 193/4885ATM 999/4885USP2 3558/4885 |
| US-10398663-B2 | Mitochondrial delivery of 3-bromopyruvate | PC, SLC25A1, TK2 | ABCB1 755/4885ATM 1336/4885USP2 4224/4885 |
| US-20140142121-A1 | MITOCHONDRIA-TARGETED ANTI-TUMOR AGENTS | HSPE1, TUFM, TK2 | ABCB1 1006/4885ATM 1463/4885USP2 2138/4885 |
| US-20170216219-A1 | THERAPEUTIC NANOPARTICLES FOR ACCUMULATION IN THE BRAIN | NLN, HSPE1, HSPA9 | ABCB1 394/4885ATM 2435/4885USP2 2142/4885 |
| US-20160184333-A1 | MITOCHONDRIA-TARGETED ANTI-TUMOR AGENTS | HSPE1, TUFM, TK2 | ABCB1 1006/4885ATM 1463/4885USP2 2138/4885 |
| US-20170087167-A1 | MODIFICATION OF DRUGS FOR INCORPORATION INTO NANOPARTICLES | NLN, PRNP, TPMT | ABCB1 7/4885ATM 3397/4885USP2 1556/4885 |
| US-20170014361-A1 | MITOCHONDRIAL DELIVERY OF 3-BROMOPYRUVATE | PC, SLC25A1, TK2 | ABCB1 755/4885ATM 1336/4885USP2 4224/4885 |
| US-10845368-B2 | Nanoparticles for mitochondrial trafficking of agents | RHOT2, TFAM, MAVS | ABCB1 321/4885ATM 3010/4885USP2 1918/4885 |
| US-20170037071-A1 | MITOCHONDRIA-TARGETING PLATINUM(IV) PRODRUG | MT-ND4, MT-CO3, COX6A1 | ABCB1 193/4885ATM 999/4885USP2 3558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.